Objective To investigate the effect of Ticagrelor combined with Aspirin in patients with coronary heart disease after percutaneous coronary intervention (PCI). Methods A total of 91 cases of patients with coronary heart disease after PCI treated in Jiaxian People’s Hospital from January 2022 to January 2023 were selected as the study objects and divided into group A (n=45) and group B (n=46) by coin tossing method. During the treatment period, there were 5 cases of shedding, and a total of 86 cases were finally completed in this study, including 43 cases in group A and 43 cases in group B. Both groups were treated with aspirin, with group A added clopidogrel and group B added ticagrelor, and both groups were treated for 12 months. Cardiac function indexes, platelet parameters and coagulation function, oxidative stress indexes, major cardiovascular adverse events (MACE) and bleeding events were compared between the two groups. Results After 12 months of treatment, the levels of left ventricular ejection fraction (LVEF), stroke volume (SV) and cardiac output (CO) in two groups were higher than those before treatment, and those in group B were higher than those in group A (P <0.05). After 12 months of treatment, the maximum platelet aggregation rate (MPAR) and fibrinogen (Fbg) levels in two groups were lower than before treatment, and the levels in group B were lower than those in group A; the levels of thrombin time (TT) and prothrombin time (PT) increased after treatments, and those in group B were higher than those in group A (P<0.05). After 3 months of treatment, the levels of superoxide dismutase (SOD) and nitric oxide (NO) in two groups were higher than before treatment, and those in group B were higher than those in group A; the level of malondialdehyde (MDA) decreased and that in group B was lower than that in group A (P<0.05). According to Fisher’s exact probability test, the incidence of MACE and bleeding in group B was 4.65% (2/43) and 6.98% (3/43), and no significant difference was observed compared with 9.30% (4/43) and 11.63% (5/43) in group A (all P>0.05). Conclusion For patients with coronary heart disease after PCI, the combination of Ticagrelor and Aspirin can improve cardiac function, regulate oxidative stress indexes, regulate platelet parameters and coagulation function, and reduce the incidence of MACE and bleeding events.